Response to the article by Lai et al. “Comment on Ormaza Vera et al. ‘Interleukin-23 inhibition associates with lower incidence of cardiovascular risk factor type diseases compared to biologic naïve patients with psoriasis: A retrospective cohort study’” - 17/07/25
Doi : 10.1016/j.jaad.2025.03.058
Ana Ormaza Vera, MD, Clinton W. Enos, MD, MS ⁎ 
Department of Dermatology, Eastern Virginia Medical School, Macon & Joan Brock Virginia Health Sciences at Old Dominion University, Norfolk, Virginia
∗Correspondence to: Clinton W. Enos, MD, MS, Department of Dermatology, Eastern Virginia Medical School, Macon & Joan Brock Virginia Health Sciences at Old Dominion University, 721 Fairfax Avenue, Suite 200, Andrews Hall, Norfolk, VA 23507Department of DermatologyEastern Virginia Medical SchoolMacon & Joan Brock Virginia Health Sciences at Old Dominion University721 Fairfax AvenueSuite 200Andrews HallNorfolkVA23507
Key words : biologics, cardiovascular risk, diabetes, dyslipidemia, hypertension, MACEs, psoriasis therapy, psoriasis
Le texte complet de cet article est disponible en PDF.
| Funding sources: The author has previously served as a consultant on an advisory board for UCB and Amgen, is an investigator for Amgen and Castle Biosciences, receives grant funding from La Roche-Posay, and has previously received research funding from the ASA/Arcutis Biotherapeutics. |
|
| IRB approval status: Not applicable. |
|
| Patient consent on File: Not applicable. |
© 2025
Publié par Elsevier Masson SAS.
Vol 93 - N° 2
P. e53-e54 - août 2025 Retour au numéro
Article précédent
- Comment on Vera et al’s “Interleukin-23 inhibition associates with lower incidence of cardiovascular risk factor type diseases compared to biologic naïve patients with psoriasis: A retrospective cohort study.”
- I-Chang Lai, James Cheng-Chung Wei
- Updates to the role of diet in atopic dermatitis
- Katherine E. Herman, Lisa A. Beck, Kirsi M. Järvinen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?